IMPEDIMED ORD
ImpediMed’s BIS technology gains recognition as NCCN includes in oncology guidelines for lymphoedema assessment
A screening platform developed by ImpediMed (ASX: IPD) for the assessment of lymphoedema is expected to increase its profile with the announcement that bioimpedance spectroscopy (BIS) has achieved inclusion in oncology guidelines released by the National Comprehensive Cancer Network (NCCN). BIS analysis is a noninvasive, low-cost procedure which can accurately measure a patient’s total body […]
AstraZeneca sources ImpediMed’s SOZO devices for upcoming clinical trial
Medical technology company ImpediMed (ASX: IPD) unveiled a timely contract valued at over $2 million for its SOZO digital health platform, which paves the way for it to be used in a clinical trial by global biopharmaceutical giant AstraZeneca. The company said around 175 of its SOZO devices will be used in a phase II […]
ImpediMed welcomes NCCN’s updated breast cancer guidelines to provide early lymphoedema screening
The National Comprehensive Care Network (NCCN) has updated its Guidelines for Breast Cancer regarding early detection and diagnosis of lymphoedema, which ImpediMed (ASX: IPD) hopes to take advantage of with its non-invasive bioimpedance spectrometry (BIS) test and Lymphoedema Prevention Program (LPP). The update follows requests from Vanderbilt University School of Nursing, Lymphatic Education and Research […]
ImpediMed offers first glimpse into PREVENT trial results
Medical device manufacturer ImpediMed (ASX: IPD) has provided an early insight into forthcoming results from its PREVENT trial by publishing “the first of a number of manuscripts” from its ongoing trial. The latest results were published in ‘Lymphatic Research and Biology’ magazine, indicating that L-Dex is “very sensitive” in the assessment of sub-clinical lymphoedema in […]